190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
October 26, 2021 18:19 ET | BioNTech SE
Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 years of age during a period when Delta was the prevalent strain10-µg...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
October 21, 2021 06:45 ET | BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...
Daten aus Phase-3-Studie von Pfizer und BioNTech zeigen hohe Wirksamkeit von COVID-19-Auffrischungsimpfung
October 21, 2021 06:45 ET | BioNTech SE
Die ersten Ergebnisse einer randomisierten, kontrollierten COVID-19 Impfstoff-Auffrischungsstudie zeigen eine relative Impfstoffwirksamkeit von 95,6 % gegen COVID-19 in einem Zeitraum, in dem Delta...
22157.jpg
Global $6.3 Bn Single-cell Analysis Markets to 2026 - Growing Focus on Personalized Medicine
October 12, 2021 07:33 ET | Research and Markets
Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Global Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instrument), Technique (Flow Cytometry, NGS, PCR,...
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
October 04, 2021 12:10 ET | BioNTech SE
NEW YORK and MAINZ, Germany, October 4, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP)...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COVID-19-Auffrischungsimpfung in der Europäischen Union
October 04, 2021 12:10 ET | BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 4. Oktober 2021—Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
October 01, 2021 08:12 ET | BioNTech SE
MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and...
BioNTech präsentiert neue klinische und präklinische Daten aus mehreren Immunonkologie-Programmen auf der 36. Jahrestagung der SITC
October 01, 2021 08:12 ET | BioNTech SE
MAINZ, Deutschland, 1. Oktober 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“), ein Unternehmen, das zukunftsweisende Immuntherapien der nächsten Generation zur...
22157.jpg
North America miRNA Sequencing and Assay Market Report 2021-2027: Widening Range of MicroRNA Applications & Rise in Funding for Genomics Research
September 22, 2021 07:28 ET | Research and Markets
Dublin, Sept. 22, 2021 (GLOBE NEWSWIRE) -- The "North America miRNA Sequencing and Assay Market 2021-2027 by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's...
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
September 22, 2021 06:02 ET | BioNTech SE
Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billionEffort contributes to companies’ pledge to deliver two billion...